Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - What's Next?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.58 and traded as low as $0.37. Vaxart shares last traded at $0.42, with a volume of 5,497,343 shares trading hands.

Analyst Ratings Changes

Separately, B. Riley decreased their price objective on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research report on Thursday, March 27th.

Vaxart Trading Down 2.4%

The business's fifty day moving average is $0.41 and its 200 day moving average is $0.58. The company has a market cap of $112.51 million, a P/E ratio of -1.21 and a beta of 1.27.

Vaxart (NASDAQ:VXRT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.07). The business had revenue of $20.88 million during the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. As a group, research analysts expect that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Institutional Trading of Vaxart

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in Vaxart in the 4th quarter worth approximately $129,000. Sequoia Financial Advisors LLC raised its stake in Vaxart by 140.9% in the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after buying an additional 35,213 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Vaxart by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock valued at $1,723,000 after purchasing an additional 57,911 shares during the period. Invesco Ltd. increased its stake in shares of Vaxart by 48.6% in the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 24,803 shares in the last quarter. Finally, Silverarc Capital Management LLC lifted its holdings in shares of Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 77,782 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.